Mesoblast Limited (NASDAQ:MESO) Q4 2019 Earnings Conference Call August 29, 2019 6:00 PM ET Company Participants Silviu Itescu ??? Chief Executive Officer Josh Muntner ??? Chief Financial Officer Conference Call Participants Jeffrey Cohen ??? Ladenburg Kalpit Patel ??? Oppenheimer Swayampakula Ramakanth ??? H.C. Wainwright Tanushree Jain ??? Bell Potter Securities Nicolette Quinn ??? Morningstar Marc Sinatra ??? Lodge Partners Operator Hello, and welcome to Mesoblast???s Financial Update and Operational Hig ...

Operational Highlights and Financial Results for the Nine Months and Quarter Ended March 31, 2019 May 2019 Nasdaq: MESO ASX: MSB CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of act ...

Mesoblast (NASDAQ:MESO) Q3 2019 Earnings Conference Call May 30, 2019 4:30 PM ET Company Participants Silviu Itescu ??? Chief Executive Officer Josh Muntner ??? Chief Financial Officer Joanne Kurtzberg ??? Distinguished Professor of Pediatrics Conference Call Participants Mark Breidenbach ??? Oppenheimer Jason McCarthy ??? Maxim Group Jeffrey Cohen ??? Ladenburg Thalmann Operator Hello, and welcome to Mesoblast's Financial Update and Operational Highlights Webcast for the Third Quarter Ended March 31, 2019. ...

Global Leader in Cellular Medicines for Inflammatory Diseases March 2019 Nasdaq: MESO ASX: MSB CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements ...

Operational Highlights and Financial Results for the Half Year Ended December 31, 2018 February 2019 Nasdaq: MESO ASX: MSB CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, ...

Company and Industry Highlights * **Company**: Mesoblast (NASDAQ: MESO) * **Industry**: Biotechnology, Cell Therapy * **Date**: February 20, 2019 Key Points: **1. Pipeline and Clinical Trials**: * **Remestemcel-L**: Phase 3 trial for steroid-refractory acute graft-versus-host disease (GVHD) completed, BLA submission expected in early 2019. * **Revascor**: Phase 3 trial for advanced heart failure completed enrollment, expected to complete within 12 months. * **MPC-06-ID**: Phase 3 trial for chronic low back pain due to disc degeneration completed enrollment, 12-month assessment for safety and efficacy expected in first half of 2019. **2. Financial Highlights**: * **Cash Position**: $92 million pro forma cash on hand as of December 31, 2018. * **Revenue**: $13.5 million for six months ended December 31, 2018. * **Milestone Payments**: Significant increase in milestone payments from licensees Takeda and Tasly. **3. Partnerships and Collaborations**: * **Tasly**: Cardiovascular partnership established, upfront payment of $40 million received. * **JCR Pharma**: Licensee for TEMCELL in Japan. * **Takeda**: Licensee for Alofisel in Europe. **4. Regulatory Updates**: * **Remestemcel-L**: Scheduled meeting with FDA in April 2019 for BLA filing. * **Revascor**: Partner Tasly plans to meet with National Medical Products Administration of China in first half of 2019. * **MPC-06-ID**: No specific regulatory updates mentioned. **5. Future Outlook**: * Company expects to achieve several key milestones in 2019, including BLA submission for Remestemcel-L and completion of Phase 3 trials for Revascor and MPC-06-ID. * Company aims to expand its commercial presence and explore additional licensing opportunities. Additional Important Points: * **Rheumatoid Arthritis Program**: Company plans to update on further data readout and explore partnership opportunities. * **Sales Force**: Company building a focused U.S. sales force for Remestemcel-L launch. * **Regenerative Medicine Advanced Therapy (RMAT) Designation**: Received RMAT designation from FDA for Revascor for reduction of gastrointestinal bleeding in patients with LVADs.